Back to search

Boston University

Preliminary comparison of major adverse outcomes in patients with nonalcoholic fatty liver disease initiated on second-line antihyperglycemic therapy

Abstract

dc:description.abstract

OBJECTIVES: To assess long-term hepatic and cardiovascular outcomes in patients with both nonalcoholic fatty liver disease (NAFLD) and type II diabetes who are initiated on treatment with second-line antihyperglycemic medications including sodium-glucose contransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). METHODS: This retrospective cohort study included patients with NAFLD and type II diabetes queried from the electronic health record of the Mass General Brigham healthcare system. Previous work by our team has created a dataset of patients with NAFLD identified from liver biopsy reports using natural language processing techniques. This was further subdivided into three cohorts based on initiation of a second-line diabetes medication. Patients were followed in an as-treated approach for liver decompensation events (i.e., ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, bleeding esophageal varices, or hepatic encephalopathy), hepatocellular carcinoma, major adverse cardiovascular events (i.e., myocardial infarction, stroke, bleeding event, or congestive heart failure), and death. Incidence rates of these outcomes were compared between the three groups. RESULTS: The incidence rate of adverse events was much lower in patients initiated on SGLT2i or GLP-1RA as compared to insulins, sulfonylureas, thiazolidinediones, or dipeptidyl peptidase-4 inhibitors. The SGLT2i and GLP-1RA cohorts were comparable with 0.20 and 0.19 events per 1,000 person-years, respectively. The other medication cohort had an event rate of 1.01 events per 1,000 person-years. CONCLUSION: Preliminary findings suggest that SGLT2i and GLP-1RA therapy may have a protective role in NAFLD patients. However, this analysis did not control for any confounding between the treatment groups. More robust comparisons are underway and will be reported in future publications.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kim, Rachel Soon-yong
Advisor dc:contributor.advisor
  • Simon, Tracey G.
ORCID dc:identifier.orcid

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/48281

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Kim, Rachel Soon-yong. Preliminary comparison of major adverse outcomes in patients with nonalcoholic fatty liver disease initiated on second-line antihyperglycemic therapy. masters thesis, Boston University, 2023. https://hdl.handle.net/2144/48281